Kolltan Pharmaceuticals
Industry
- Biotechnology
- Large Molecule
- Antibodies
- Large Molecule
- Pharmaceuticals
Other Names/Subsidiaries
- Xetrios Therapeutics Inc.
- Celldex Therapeutics, Inc.
Latest on Kolltan Pharmaceuticals
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions that occurred from March 30-April 1
Financings Biopharma companies closed out 2016 with $9.6 billion in financing. ( See Exhibit 1. ) Not only was this a 30% increase over Q3's $7.4 billion, it was also the strongest quarter of the year
Following the completion of its privatization at the end of 2015 after delisting from the New York Stock Exchange, WuXi has officially kicked off a new round of capital-raising operation. On Jan. 4, H
IN VITRO DIAGNOSTICS Alliances Allergan PLC T2 Biosystems Inc. T2 Biosystems Inc. and Allergan PLC are teaming up to develop a diagnostic panel to detect Gram-negative bacteria and antibiotic